PET/MR in Oncology: Non-18F-FDG tracers for routine applications

Journal of Nuclear Medicine

Volumn 55, Issue 6 SUPPL. 2, 2014, Pages

  Rauscher, Isabel ^a   Eiber, Matthias ^b   Souvatzoglou, Michael ^b   Schwaiger, Markus ^b   Beer, Ambros J ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Oncology

Indexed keywords

CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SOMATOSTATIN RECEPTOR;

BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RECURRENCE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HUMAN; LYMPH NODE METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WHOLE BODY MRI; WHOLE BODY PET;

EID: 84903130788     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129536     Document Type: Review

References (67)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
2. Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(suppl 1):3-7.
3. Teunissen JJ, Kwekkeboom DJ, Valkema R, et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(suppl 1):S27-S51.
4. Wong KK, Waterfield RT, Marzola MC, et al. Contemporary nuclear medicine imaging of neuroendocrine tumours. Clin Radiol. 2012;67:1035-1050.
5. Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770-1780.
6. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
7. Baum RP, Prasad V, Hommann M, et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res. 2008;170:225-242.
8. 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
9. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-78. (Pubitemid 41702624)
10. Li RK, Zhao J, Rao SX, et al. Primary hepatic neuroendocrine carcinoma: MR imaging findings including preliminary observation on diffusion-weighted imaging. Abdom Imaging. 2013;38:1269-1276.
11. 68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13:63-72.
12. 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48:263-272.
13. 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013;48:273-279.
14. Regier M, Schwarz D, Henes FO, et al. Diffusion-weighted MR-imaging for the detection of pulmonary nodules at 1.5 Tesla: intraindividual comparison with multidetector computed tomography. J Med Imaging Radiat Oncol. 2011;55: 266-274.
15. Mayerhoefer ME, Ba-Ssalamah A, Weber M, et al. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol. 2013;23:1978-1985.
16. Stolzmann P, Veit-Haibach P, Chuck N, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol. 2013;48:241-246.
17. Rauscher I, Eiber M, Fürst S, et al. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med . March 20, 2014 [Epub ahead of print].
18. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
19. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741. (Pubitemid 36384965)
20. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523. (Pubitemid 36132976)
21. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-385. (Pubitemid 38622589)
22. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46-66.
23. Farsad M, Schwarzenbock S, Krause BJ. PET/CT and choline: diagnosis and staging. Q J Nucl Med Mol Imaging. 2012;56:343-353.
24. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med. 2013;54: 1685-1688.
25. 11C] choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-3759.
26. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-1649.
27. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954-960, discussion 60.
28. Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012;2: 318-330.
29. Heck MM, Souvatzoglou M, Retz M, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41: 694-701.
30. Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040-1048.
31. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
32. 11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1486-1499.
33. 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55: 223-232.
34. 11C-choline-PET/CT [abstract]. J Nucl Med. 2013;54(suppl 2):104P.
35. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010;45:15-23.
36. 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125-130.
37. Beer AJ, Eiber M, Souvatzoglou M, et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12:181-191.
38. 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013;34: 935-945.
39. 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-168.
40. Seitz M, Shukla-Dave A, Bjartell A, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol. 2009;55:801-814.
41. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59: 962-977.
42. 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer. Clin Nucl Med. 2012;37:918-919.
43. 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-1400.
44. Roethke MC, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancerpreliminary results. Eur Urol. 2013;64:862-864.
45. 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1629-1630.
46. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
47. 18F-choline- based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41: 11-20.
48. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887-897.
49. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR. 2001;177:229-236. (Pubitemid 32578088)
50. Imamura F, Kuriyama K, Seto T, et al. Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer. 2000;27:189-197. (Pubitemid 30105658)
51. 18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822-830.
52. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462-469.
53. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332-334.
54. 18F-fluoride PET scans. J Nucl Med. 2004;45:1493-1500.
55. 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278.
56. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-2389. (Pubitemid 29368236)
57. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
58. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
59. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356-1367. (Pubitemid 43733488)
60. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31:50-61. (Pubitemid 32060652)
61. 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014;55:191-197.
62. Samarin A, Burger C, Wollenweber SD, et al. PET/MR imaging of bone lesions: implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging. 2012;39:1154-1160.
63. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol. 2007;36:1109-1119. (Pubitemid 350112367)
64. 18F- fluoride ion PET bone scanning. AJR. 2006;186:1783-1786.
65. Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123-129. (Pubitemid 29095482)
66. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci. 2007;6:147-155.
67. 11C-choline PET/CT for detection of bone metastases. Radiology. 2008;249:1017-1025.